The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Duvelisib and FCR: a recipe for success in CLL
Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however, has shown impressive responses, and even curative effects in young patients, especially those with IGHV mutations. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Matthew Davids, MD, MSc, of the Dana-Farber Cancer Institute, Boston, MA, speaks about a study combining novel agent duvelisib with FCR in young CLL patients (dFCR; NCT02158091). Dr Davids discusses the rationale behind the study, and the toxicities experienced. Finally, he points out the dramatic efficacy rates, with ~75% of patients reaching MRD negativity, including patients without IGHV mutations.
